{"id":5111,"date":"2014-05-23T08:42:17","date_gmt":"2014-05-23T12:42:17","guid":{"rendered":"https:\/\/themedicalxchange.com\/2014\/05\/23\/semaine-des-maladies-digestives-de-2014-digestiv-2\/"},"modified":"2021-09-13T16:03:37","modified_gmt":"2021-09-13T20:03:37","slug":"semaine-des-maladies-digestives-de-2014-digestiv-2","status":"publish","type":"post","link":"https:\/\/themedicalxchange.com\/fr\/2014\/05\/23\/semaine-des-maladies-digestives-de-2014-digestiv-2\/","title":{"rendered":"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III"},"content":{"rendered":"<p>Comparativement \u00e0 celle de l\u2019IFN, l\u2019efficacit\u00e9 des nouveaux agents est attribu\u00e9e \u00e0 leur aptitude \u00e0 inhiber les processus enzymatiques cruciaux intervenant dans la r\u00e9plication et la survie du VHC. Les r\u00e9sultats obtenus avec ces agents sont impressionnants. En effet, au cours de deux \u00e9tudes multinationales pr\u00e9sent\u00e9es dans le cadre de la Semaine des maladies digestives de cette ann\u00e9e et r\u00e9alis\u00e9es chez des patients ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s auparavant, l\u2019ABT-450 rehauss\u00e9 de ritonavir et alli\u00e9 \u00e0 une deuxi\u00e8me antiprot\u00e9ase, l\u2019ABT-267, ainsi qu\u2019\u00e0 l\u2019ABT-333, une antipolym\u00e9rase, a permis d\u2019obtenir un taux de RVS de 96\u00a0% chez les patients infect\u00e9s par le g\u00e9notype\u00a01b du VHC, qu\u2019il soit administr\u00e9 en association avec de la ribavirine ou non. Or les taux de RVS enregistr\u00e9s avec ce sch\u00e9ma th\u00e9rapeutique, qui est connu sous le nom de 3D, ont \u00e9t\u00e9 encore plus \u00e9lev\u00e9s chez les patients jamais trait\u00e9s auparavant. \u00ab\u00a0En plus d\u2019\u00eatre tr\u00e8s efficace, cette association m\u00e9dicamenteuse est bien tol\u00e9r\u00e9e par les patients de sorte que peu d\u2019entre eux abandonnent le traitement, un facteur qui y est certainement pour beaucoup dans l\u2019obtention de taux de RVS aussi \u00e9lev\u00e9s\u00a0\u00bb, a d\u00e9clar\u00e9 le D<sup>r<\/sup>\u00a0Ira M.\u00a0Jacobson, chercheur principal de l\u2019\u00e9tude SAPPHIRE\u00a0II, l\u2019une des deux \u00e9tudes mentionn\u00e9es pr\u00e9c\u00e9demment. Cette \u00e9tude a \u00e9t\u00e9 men\u00e9e \u00e0 double insu et avec r\u00e9partition al\u00e9atoire chez des patients ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s auparavant; 297\u00a0sujets ont suivi le traitement actif (3D), tandis que 97\u00a0patients ont re\u00e7u des placebos appari\u00e9s. Au bout de 12\u00a0semaines, les taux de RVS obtenus \u00e9taient comparables que les sujets soient infect\u00e9s par le g\u00e9notype\u00a01a ou le g\u00e9notype\u00a01b (96\u00a0% et 96,7\u00a0%, respectivement) du VHC. La deuxi\u00e8me \u00e9tude, une \u00e9tude men\u00e9e en mode ouvert appel\u00e9e PEARL\u00a0II, a \u00e9t\u00e9 r\u00e9alis\u00e9e exclusivement chez des patients infect\u00e9s par le g\u00e9notype\u00a01b du VHC, indemnes de cirrhose et ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s. Les 187\u00a0participants ont \u00e9t\u00e9 r\u00e9partis al\u00e9atoirement de mani\u00e8re \u00e0 recevoir le sch\u00e9ma 3D avec ou sans ribavirine. \u00c0 la 12<sup>e<\/sup>\u00a0semaine, les taux de RVS se chiffraient \u00e0 96,6\u00a0% dans le groupe ayant re\u00e7u le sch\u00e9ma 3D et de la ribavirine et \u00e0 100\u00a0% chez ceux qui avaient \u00e9t\u00e9 trait\u00e9s au moyen du sch\u00e9ma 3D seulement <a href=\"javascript:void(0)\" class=\"show-image\" data-index=\"0\">(Fig. 1)<\/a>. Les deux sch\u00e9mas th\u00e9rapeutiques ont \u00e9t\u00e9 bien tol\u00e9r\u00e9s et les taux d\u2019abandon, bas, m\u00eame si le traitement sans ribavirine a donn\u00e9 lieu \u00e0 des r\u00e9sultats de laboratoire plus faibles, tels qu\u2019une baisse de l\u2019h\u00e9moglobin\u00e9mie. D\u2019autres donn\u00e9es recueillies sur des sch\u00e9mas th\u00e9rapeutiques sans IFN semblent \u00e9galement prometteuses. Au cours de l\u2019essai ION-2, qui a servi \u00e0 \u00e9valuer une association form\u00e9e de sofosbuvir, une antipolym\u00e9rase et de l\u00e9dipasvir, une antiprot\u00e9ase, 440\u00a0patients ayant d\u00e9j\u00e0 \u00e9t\u00e9 trait\u00e9s auparavant ont \u00e9t\u00e9 r\u00e9partis al\u00e9atoirement de mani\u00e8re \u00e0 recevoir ces deux m\u00e9dicaments avec ou sans ribivarine. Cet effectif de sujets \u00e9tait moins homog\u00e8ne que ceux des \u00e9tudes SAPPHIRE\u00a0II et PEARL\u00a0II pour ce qui \u00e9tait des g\u00e9notypes du VHC, mais les taux de RVS ont quand m\u00eame atteint les 95\u00a0% que les sujets aient pris de la ribavirine ou non, et l\u2019incidence des effets ind\u00e9sirables graves a \u00e9t\u00e9 faible. Ces \u00e9tudes ont plusieurs implications importantes. Premi\u00e8rement, les nouveaux sch\u00e9mas th\u00e9rapeutiques permettent apparemment d\u2019obtenir des taux de RVS comparables d\u2019un g\u00e9notype du VHC \u00e0 l\u2019autre. Selon les donn\u00e9es pr\u00e9sent\u00e9es lors de la Semaine des maladies digestives, cette efficacit\u00e9 s\u2019\u00e9tendait m\u00eame aux patients qui avaient peu r\u00e9agi, voire pas du tout, aux traitements les plus muscl\u00e9s \u00e0 base d\u2019IFN offerts pr\u00e9c\u00e9demment. Deuxi\u00e8mement, la r\u00e9ussite du traitement \u00e0 l\u2019aide de ces sch\u00e9mas th\u00e9rapeutiques extr\u00eamement cibl\u00e9s risque peu d\u2019\u00eatre compromise \u00e0 cause d\u2019effets ind\u00e9sirables graves. D\u2019apr\u00e8s le D<sup>r<\/sup>\u00a0Jacobson, cela met tous les patients infect\u00e9s par le VHC sur un pied d\u2019\u00e9galit\u00e9. \u00ab\u00a0Ces donn\u00e9es sont tr\u00e8s positives et laissent entrevoir une occasion en or de r\u00e9duire le risque de complications \u00e0 long terme de l\u2019infection par le VHC chez la majorit\u00e9 et peut-\u00eatre m\u00eame tous les patients qui en sont atteints\u00a0\u00bb, a-t-il ajout\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><b> Chicago <\/b> \u2013 Il fait de moins en moins de doute que des sch\u00e9mas th\u00e9rapeutiques exempts d\u2019interf\u00e9ron (IFN) dirig\u00e9s contre le virus de l\u2019h\u00e9patite C (VHC) seront homologu\u00e9s sous peu. Une s\u00e9rie d\u2019\u00e9tudes pr\u00e9sent\u00e9es dans le cadre de conf\u00e9rences d\u2019importance majeure au cours des derniers mois, dont la Semaine des maladies digestives de 2014, ont \u00e9tabli un parall\u00e8le entre les plus efficaces de ces traitements et des taux de r\u00e9ponse virologique soutenue (RVS) sup\u00e9rieurs \u00e0 90 %, et ce m\u00eame chez des patients infect\u00e9s par un g\u00e9notype du VHC particuli\u00e8rement r\u00e9fractaire chez lesquels les traitements ant\u00e9rieurs avaient \u00e9chou\u00e9.<\/p>\n","protected":false},"author":1,"featured_media":5112,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"tags":[432,523,291],"class_list":["post-5111","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-ddw-fr","tag-extract-fr","tag-gastroenterologie","area_tag-gastroenterologie"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III - The Medical Xchange<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III - The Medical Xchange\" \/>\n<meta property=\"og:description\" content=\"Chicago \u2013 Il fait de moins en moins de doute que des sch\u00e9mas th\u00e9rapeutiques exempts d\u2019interf\u00e9ron (IFN) dirig\u00e9s contre le virus de l\u2019h\u00e9patite C (VHC) seront homologu\u00e9s sous peu. Une s\u00e9rie d\u2019\u00e9tudes pr\u00e9sent\u00e9es dans le cadre de conf\u00e9rences d\u2019importance majeure au cours des derniers mois, dont la Semaine des maladies digestives de 2014, ont \u00e9tabli un parall\u00e8le entre les plus efficaces de ces traitements et des taux de r\u00e9ponse virologique soutenue (RVS) sup\u00e9rieurs \u00e0 90 %, et ce m\u00eame chez des patients infect\u00e9s par un g\u00e9notype du VHC particuli\u00e8rement r\u00e9fractaire chez lesquels les traitements ant\u00e9rieurs avaient \u00e9chou\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/\" \/>\n<meta property=\"og:site_name\" content=\"The Medical Xchange\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-23T12:42:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-13T20:03:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/05\/EX_7007_DDW_FR_Fig_1.PNG\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"nuagelab\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"nuagelab\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/\"},\"author\":{\"name\":\"nuagelab\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#\\\/schema\\\/person\\\/c4e17cbf7de41a40b9366989481cfc4b\"},\"headline\":\"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III\",\"datePublished\":\"2014-05-23T12:42:17+00:00\",\"dateModified\":\"2021-09-13T20:03:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/\"},\"wordCount\":781,\"image\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/05\\\/EX_7007_DDW_FR_Fig_1.PNG\",\"keywords\":[\"DDW\",\"extract\",\"Gastroent\u00e9rologie\"],\"articleSection\":[\"Non classifi\u00e9(e)\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/\",\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/\",\"name\":\"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III - The Medical Xchange\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/05\\\/EX_7007_DDW_FR_Fig_1.PNG\",\"datePublished\":\"2014-05-23T12:42:17+00:00\",\"dateModified\":\"2021-09-13T20:03:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#\\\/schema\\\/person\\\/c4e17cbf7de41a40b9366989481cfc4b\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/05\\\/EX_7007_DDW_FR_Fig_1.PNG\",\"contentUrl\":\"https:\\\/\\\/themedicalxchange.com\\\/wp-content\\\/uploads\\\/2014\\\/05\\\/EX_7007_DDW_FR_Fig_1.PNG\",\"width\":960,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/2014\\\/05\\\/23\\\/digestive-disease-week-ddw-2014-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/\",\"name\":\"The Medical Xchange\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/themedicalxchange.com\\\/en\\\/#\\\/schema\\\/person\\\/c4e17cbf7de41a40b9366989481cfc4b\",\"name\":\"nuagelab\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g\",\"caption\":\"nuagelab\"},\"url\":\"https:\\\/\\\/themedicalxchange.com\\\/fr\\\/author\\\/nuagelab\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III - The Medical Xchange","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III - The Medical Xchange","og_description":"Chicago \u2013 Il fait de moins en moins de doute que des sch\u00e9mas th\u00e9rapeutiques exempts d\u2019interf\u00e9ron (IFN) dirig\u00e9s contre le virus de l\u2019h\u00e9patite C (VHC) seront homologu\u00e9s sous peu. Une s\u00e9rie d\u2019\u00e9tudes pr\u00e9sent\u00e9es dans le cadre de conf\u00e9rences d\u2019importance majeure au cours des derniers mois, dont la Semaine des maladies digestives de 2014, ont \u00e9tabli un parall\u00e8le entre les plus efficaces de ces traitements et des taux de r\u00e9ponse virologique soutenue (RVS) sup\u00e9rieurs \u00e0 90 %, et ce m\u00eame chez des patients infect\u00e9s par un g\u00e9notype du VHC particuli\u00e8rement r\u00e9fractaire chez lesquels les traitements ant\u00e9rieurs avaient \u00e9chou\u00e9.","og_url":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/","og_site_name":"The Medical Xchange","article_published_time":"2014-05-23T12:42:17+00:00","article_modified_time":"2021-09-13T20:03:37+00:00","og_image":[{"width":960,"height":720,"url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/05\/EX_7007_DDW_FR_Fig_1.PNG","type":"image\/png"}],"author":"nuagelab","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"nuagelab","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#article","isPartOf":{"@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/"},"author":{"name":"nuagelab","@id":"https:\/\/themedicalxchange.com\/en\/#\/schema\/person\/c4e17cbf7de41a40b9366989481cfc4b"},"headline":"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III","datePublished":"2014-05-23T12:42:17+00:00","dateModified":"2021-09-13T20:03:37+00:00","mainEntityOfPage":{"@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/"},"wordCount":781,"image":{"@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#primaryimage"},"thumbnailUrl":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/05\/EX_7007_DDW_FR_Fig_1.PNG","keywords":["DDW","extract","Gastroent\u00e9rologie"],"articleSection":["Non classifi\u00e9(e)"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/","url":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/","name":"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III - The Medical Xchange","isPartOf":{"@id":"https:\/\/themedicalxchange.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#primaryimage"},"image":{"@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#primaryimage"},"thumbnailUrl":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/05\/EX_7007_DDW_FR_Fig_1.PNG","datePublished":"2014-05-23T12:42:17+00:00","dateModified":"2021-09-13T20:03:37+00:00","author":{"@id":"https:\/\/themedicalxchange.com\/en\/#\/schema\/person\/c4e17cbf7de41a40b9366989481cfc4b"},"breadcrumb":{"@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#primaryimage","url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/05\/EX_7007_DDW_FR_Fig_1.PNG","contentUrl":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/05\/EX_7007_DDW_FR_Fig_1.PNG","width":960,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/themedicalxchange.com\/en\/2014\/05\/23\/digestive-disease-week-ddw-2014-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/themedicalxchange.com\/en\/"},{"@type":"ListItem","position":2,"name":"Des traitements sans interf\u00e9ron dirig\u00e9s contre l\u2019h\u00e9patite C sont en voie d\u2019homologation : donn\u00e9es issues d\u2019\u00e9tudes de Phase III"}]},{"@type":"WebSite","@id":"https:\/\/themedicalxchange.com\/en\/#website","url":"https:\/\/themedicalxchange.com\/en\/","name":"The Medical Xchange","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/themedicalxchange.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/themedicalxchange.com\/en\/#\/schema\/person\/c4e17cbf7de41a40b9366989481cfc4b","name":"nuagelab","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4264331b8ad626daf710d626ffc98eb71b9ccc45de1c39ed9511f9f5af72d645?s=96&d=mm&r=g","caption":"nuagelab"},"url":"https:\/\/themedicalxchange.com\/fr\/author\/nuagelab\/"}]}},"_links":{"self":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/posts\/5111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/comments?post=5111"}],"version-history":[{"count":0,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/posts\/5111\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/media\/5112"}],"wp:attachment":[{"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/media?parent=5111"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/themedicalxchange.com\/fr\/wp-json\/wp\/v2\/tags?post=5111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}